Oncolytics Biotech, Inc. Common Shares closed at $0.42 on Nov 4, up 8.92%, 66.6% below its 52-week closing high. Volume of 873.7K shares was 0.66× its 20-day average (below normal).
Split-adjusted performance: -29.0% over one month, -53.8% over six months, -61.0% over one year.
Short interest was 9.0M shares at the Oct 15 settlement, up 22.4% from the prior report (7.4% of float, 5.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ONCYOncolytics Biotech | $0.4248 | +8.92% | −53.8% | — | — | — | $55.7M | |
| RFLRafael Holdings | $1.07 | −0.93% | −14.4% | −30.3% | −3760.7% | — | $55.8M | Compare |
| BOLDBoundless Bio | $2.40 | +0.84% | +51.9% | — | — | — | $55.5M | Compare |
| HRTXHeron Therapeutics | $0.2986 | +4.88% | −77.2% | +1.3% | −14.6% | — | $56.7M | Compare |
| RNTXRein Therapeutics | $0.6587 | −1.32% | −43.7% | — | — | — | $56.8M | Compare |
| TLPHTalphera | $1.05 | +0.96% | +20.7% | — | — | — | $54.5M | Compare |
| XLOXilio Therapeutics | $8.71 | +0.35% | +10.3% | +131.2% | −34.1% | — | $57.3M | Compare |
| OSTXOS Therapies Incorporated | $1.15 | −0.86% | −33.5% | — | — | — | $53.8M | Compare |
| CTORCitius Oncology | $0.5470 | −0.55% | −39.8% | — | −597.4% | — | $57.9M | Compare |
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
